drugset / Trial / NCT00038376
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).
Timeline
- Start
- 1990-05-08
- Primary completion
- 2005-06-30
- Completion
- 2005-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isotretinoin | Other / unclassified | 0.5 mg/kg | Oral |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 3e+06 iu | Subcutaneous |